Gaush Meditech Ltd. provided earnings guidance for the year ended December 31, 2022. The company expects the group will record a net loss of approximately RMB 335.3 million to RMB 370.5 million for fiscal year 2022, representing an increase in net loss by approximately 75.0% to 93.4% as compared to that of approximately RMB 191.6 million for the financial year ended December 31, 2021. The increase in net loss was primarily due to the combining impact of (i) fair value losses on the convertible redeemable preferred shares of the Company and (ii) the foreign exchange losses relating to the Preferred Shares denominated in USD as a result of depreciation of RMB exchange rate against USD in 2022 of approximately RMB 447.1 million to RMB 494.1 million as compared to that of approximately RMB 337.7 million for fiscal year 2021.